



Lakes District Health Board
Corner Arawa and Ranolf Streets (Pukeroa Street)
Private Bag 3023, Rotorua Mail Centre
Rotorua 3046, New Zealand

27 May 2022

Subject: Official Information Act Request re: COVID-19 treatments

Thank you for your request for information under the Official Information Act received by Lakes DHB on 29 April 2022. You have asked;

Can the DHB please advise how many courses of the following Covid-19 treatments have been dispensed to both inpatients and outpatients between January 1 and April 28:

- ***Baricitinib (Olumiant)***
- ***Casirivimab with imdevimab (Ronapreve)***
- ***Nirmatrelvir and Ritonavir (Paxlovid)***
- ***Remdesivir (Veklury)***
- ***Tocilizumab (Actemra)***

Please note these pharmaceutical products are not limited to pure COVID-19 treatment. For example, tocilizumab is also used for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis, therefore should not be considered as COVID-19 treatment only.

Our pharmacy inventory system does not differentiate the purpose of the usage and for this reason, a careful analysis and consideration is required when viewing these numbers. Also, we do not hold information separately for the total number of pharmaceutical interventions provided for COVID-19 virus, therefore require substantial research to go through each clinical notes.

Also, the therapy duration may have changed during the period which means the number of vials do not reflect the number of patients treated. For example, remdesivir is used purely for COVID-19 and its duration of therapy has changed from 5 days to 3 days.

Below numbers are the total number of patients who received the drug during their hospital stay between 01 May 2020 and 29 April 2022.

Baricitinib (Olumiant)	0
Casirivimab with imdevimab (Ronapreve)	0
Nirmatrelvir and Ritonavir (Paxlovid)	0
Remdesivir (Veklury)	14
Tocilizumab (Actemra)	21